Literature DB >> 3924142

Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation.

R A Marlar, J Endres-Brooks, C Miller.   

Abstract

This study was undertaken to determine the levels of protein C antigen and activity and protein C inhibitor in sequential plasma samples of disseminated intravascular coagulation (DIC) patients. Our normal range for both protein C antigen and activity is 70 to 130 U/dL, and protein C inhibitor is 65 to 135 U/dL. A decreased level of protein C activity was found in 96% of the plasma samples from individuals with DIC; the protein C antigen was decreased in 73%. The inhibitor of protein C was decreased in all samples. Analysis of serial samples from patients with DIC reveals that protein C activity and antigen and protein C inhibitor decrease progressively during the initial stages of DIC and remain at a low level for 24 to 48 hours before gradually returning toward normal in nonfatal cases. The protein C activity decreases in parallel with protein C inhibitor and is lower than protein C antigen. In a fatal case of DIC, protein C activity and protein C inhibitor rapidly decreased to undetectable levels; however, protein C antigen was gradually decreasing but still detectable at time of death. In DIC, a discrepancy initially occurs between the activity and antigen of protein C, suggesting a complex with the inhibitor or other inactive forms of protein C. Protein C appears to play a major role in the control of DIC.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924142

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.

Authors:  Aleksandar Karamarkovic; Dejan Radenkovic; Natasa Milic; Vesna Bumbasirevic; Branislav Stefanovic
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

2.  [Malaria tropica with activation of blood coagulation and detection of tumor necrosis factor (NF-alpha) in serum].

Authors:  C J Hemmer; P Kern; K P Radtke; R E Egbring; P P Nawroth; M Dietrich
Journal:  Klin Wochenschr       Date:  1990-03-05

Review 3.  Clinical relevance of protein C.

Authors:  I Pabinger
Journal:  Blut       Date:  1986-08

Review 4.  Coagulation disorders in septic shock.

Authors:  L G Thijs; J P de Boer; M C de Groot; C E Hack
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  [The clinical importance of protein C and S deficiency for surgical patients].

Authors:  H Rabl; H Fruhwirth
Journal:  Langenbecks Arch Chir       Date:  1992

6.  A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.

Authors:  Nobuo Aoki; Tamotsu Matsuda; Hidehiko Saito; Kiyoshi Takatsuki; Kenji Okajima; Hoyu Takahashi; Junki Takamatsu; Hidesaku Asakura; Nobuya Ogawa
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

7.  Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases.

Authors:  F Leclerc; J Hazelzet; B Jude; W Hofhuis; V Hue; A Martinot; E Van der Voort
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

8.  [Immunologic and functional protein C determination in various internal diseases].

Authors:  K H Zurborn; H Broers; W Kirch; N Jäger; H D Bruhn
Journal:  Klin Wochenschr       Date:  1987-10-01

9.  Discovery of a genetic polymorphism of human plasma protein C inhibitor (PCI): genetic survey utilizing isoelectric focusing followed by immunoblotting, immunological and biochemical characterization.

Authors:  T Yasuda; D Nadano; R Iida; Y Tanaka; M Nakanaga; K Kishi
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

10.  New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study.

Authors:  Hiroyasu Ishikura; Takeshi Nishida; Akira Murai; Yoshihiko Nakamura; Yuhei Irie; Junichi Tanaka; Takehiro Umemura
Journal:  Crit Care       Date:  2014-01-20       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.